JULY/AUGUST 2001

Vol 8, No 4 CME Pretest

This Journal provides 4 hours of Category 1 Continuing Medical Education

Complimentary CME Credits

Physicians can earn 4 credit hours of Category 1 for the Physician's Recognition Award of the American Medical Association by reading the material in this issue and successfully answering the questions in the posttest at the end of this issue. Complete instructions are given on the posttest pages. Successfully answering 30 or more questions will earn 4 credit hours.

Educational Objectives

After reading this issue of Cancer Control, clinicians will be expected to:

• organize optimal staging for NSCLC,
  

• discuss surgical approaches to localized NSCLC,
  

• understand the role of chemotherapy in the treatment of advanced NSCLC,
  

• describe endobronchial treattment options for advanced lung cancer, and

• be aware of advances in expandable endoprostheses for
  children with malignant bone tumors.

This program was planned in accordance with ACCME Essentials.

Release Date: July 1, 2001
Expiration Date: July 1, 2002

1. Pieterman et al have compared PET with CT to stage mediastinal lymph nodes in patients with NSCLC. The sensitivity and specificity of CT was 75% and 66%, respectively. What were the data for PET?

              Sensitivity         Specificity
a.         98%                   54%
b.         91%                   86%
c.         82%                   73%
d.         82%                   56%

2. Which treatment modality increases survival rates of patients with stages I and II NSCLC who have received optimal curative-intent surgical resection?

a. neoadjuvant chemotherapy
b. adjuvant chemotherapy
c. adjuvant radiation therapy
d. none of the above

3. A trial of vinorelbine vs best supportive care for patients over age 70 with advanced NSCLC reported a 1-year survival of 14% for best supportive care. What was the result for the vinorelbine group?

a. 5%
b. 8%
c. 15%
d. 32%